Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 4/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1614607 | 0.80 | CETP (0.47) | CETPMBOAT4MEN1KMT2AMAPK1 | |
| SCHEMBL1614849 | 0.80 | CETP (0.47) | CETPMBOAT4MEN1KMT2AMAPK1 | |
| SCHEMBL7451131 | 0.78 | CETP (0.47) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL8709296 | 0.78 | MBOAT4 (0.45) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL10389226 | 0.77 | CETP (0.44) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL9116193 | 0.77 | CETP (0.44) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL6811511 | 0.76 | MBOAT4 (0.43) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL9221499 | 0.76 | CETP (0.43) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL29307029 | 0.76 | CETP (0.43) | CETPMBOAT4GAAMEN1KMT2A | |
| SCHEMBL16587991 | 0.75 | TSHR (0.40) | CETPGAAMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051293-B2 | Process for preparing episulfide compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107350-A1 | Process for Preparing Episulfide Compounds | TST, EPHX2, STS | CETP 1147/4885MBOAT4 3428/4885GAA 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.